Apogee Therapeutics (APGE) Price & Analysis

Compare

330 Followers

APGE Stock Chart & Stats

$55.00

-$0.82(-1.65%)

At close: Jan 08 4:00 PM EST

$55.00

-$0.82(-1.65%)

Day’s Range― - ―

52-Week Range$26.20 - $63.50

Previous CloseN/A

Volume109.80K

Average Volume (3M)831.09K

Market Cap

$3.69B

Enterprise Value$2.04B

Total Cash (Recent Filing)$505.42M

Total Debt (Recent Filing)$10.85M

Price to Earnings (P/E)―

Beta1.25

Next Earnings

Nov 18, 2025

EPS Estimate

-1.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.13

Shares Outstanding53,060,990

10 Day Avg. Volume693,192

30 Day Avg. Volume831,086

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.55

Enterprise Value/Revenue15.72K

Enterprise Value/Gross Profit-3.46K

Enterprise Value/Ebitda-7.55

Forecast

1Y Price Target

$93.57

Price Target Upside70.13% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)-4.5

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Efficacy In Atopic DermatitisAPG777's data exceeded expectations with a 66.9% EASI-75 improvement from baseline and 42.5% placebo-adjusted rate, even considering historically high placebo rates.

Financial StabilityAPGE has sufficient cash to fund operations into 1Q28, supporting its financial stability and ongoing development plans.

Maintenance Dosing And Safety ProfileAPG777 is very well-positioned to move forward with a once quarterly maintenance dosing schedule.

Bears Say

Apogee Therapeutics News

Apogee Therapeutics price target raised to $70 from $60 at RBC Capital

RBC Capital analyst Brian Abrahams raised the firm’s price target on Apogee Therapeutics (APGE) to $70 from $60...

4d ago

APGE

Craig-Hallum bullish on Apogee Therapeutics, initiates with a Buy

As previously reported, Craig-Hallum initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $109 price target...

4d ago

APGE

Apogee Therapeutics initiated with a Buy at Craig-Hallum

Craig-Hallum initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $109 price target Published first on...

5d ago

APGE

Apogee Therapeutics initiated with an Outperform at Mizuho

Mizuho analyst Joseph Catanzaro initiated coverage of Apogee Therapeutics (APGE) with an Outperform rating and $105 price target...

18d ago

APGE

Short Report: Fluence Energy short interest at record high

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest...

19d ago

NNE

APGE

3 Best Stocks to Buy Now, 10/17/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

22d ago

APGE

Apogee Therapeutics price target lowered to $82 from $87 at BofA

BofA analyst Tim Anderson lowered the firm’s price target on Apogee Therapeutics (APGE) to $82 from $87 and...

29d ago

APGE

Apogee Therapeutics 6.95M share Spot Secondary priced at $41.00

Jefferies, BofA, Guggenheim, TD Cowen and BTIG acted as joint book running managers for the offering. Published first...

30d ago

APGE

Apogee Therapeutics’ APG777 Study: A Potential Breakthrough in Atopic Dermatitis Treatment

Apogee Therapeutics, Inc. (($APGE)) announced an update on their ongoing clinical study. Apogee Therapeutics, Inc. is conducting a...

11d ago

APGE

Apogee Therapeutics’ New Study on Atopic Dermatitis: What Investors Need to Know

Apogee Therapeutics, Inc. (($APGE)) announced an update on their ongoing clinical study. Apogee Therapeutics, Inc. is conducting a...

11d ago

APGE

Apogee Therapeutics’ Promising Update on Long-term APG777 Study for Atopic Dermatitis

Apogee Therapeutics, Inc. (($APGE)) announced an update on their ongoing clinical study. Apogee Therapeutics, Inc. is conducting a...

11d ago

APGE

Mizuho Securities Recommends Buy for Apogee Therapeutics Due to Promising APG777 Efficacy in Th2 Inflammatory Diseases

, an analyst from Mizuho Securities, has initiated a new Buy rating on Apogee Therapeutics (APGE). Mizuho Securities...

18d ago

APGE

Apogee Therapeutics Raises $323.3 Million in Offering

Apogee Therapeutics ( ($APGE) ) has shared an update. On October 8, 2025, Apogee Therapeutics entered into an...

29d ago

APGE

Buy Recommendation for Apogee Therapeutics: Promising Clinical Developments and Strategic Financial Moves

Analyst Julian Harrison of BTIG reiterated a Buy rating on Apogee Therapeutics, retaining the price target of $115.00....

29d ago

APGE

APGE FAQ

What was Apogee Therapeutics’s price range in the past 12 months?

Apogee Therapeutics lowest stock price was $26.20 and its highest was $63.50 in the past 12 months.

What is Apogee Therapeutics’s market cap?

Apogee Therapeutics’s market cap is $3.69B.

When is Apogee Therapeutics’s upcoming earnings report date?

Apogee Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 10 days.

How were Apogee Therapeutics’s earnings last quarter?

Apogee Therapeutics released its earnings results on Aug 11, 2025. The company reported -$1.13 earnings per share for the quarter, missing the consensus estimate of -$1.094 by -$0.036.

Is Apogee Therapeutics overvalued?

According to Wall Street analysts Apogee Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Apogee Therapeutics pay dividends?

Apogee Therapeutics does not currently pay dividends.

What is Apogee Therapeutics’s EPS estimate?

Apogee Therapeutics’s EPS estimate is -1.18.

How many shares outstanding does Apogee Therapeutics have?

Apogee Therapeutics has 53,060,990 shares outstanding.

What happened to Apogee Therapeutics’s price movement after its last earnings report?

Apogee Therapeutics reported an EPS of -$1.13 in its last earnings report, missing expectations of -$1.094. Following the earnings report the stock price went down -2.091%.

Which hedge fund is a major shareholder of Apogee Therapeutics?

Currently, no hedge funds are holding shares in APGE

Apogee Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-34.12%

Trailing 12-Months

Asset Growth

-17.85%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Apogee Therapeutics

Apogee Therapeutics (APGE) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for immunological and inflammatory diseases. The company leverages advanced scientific research and technologies to address unmet medical needs in these areas, aiming to improve patient outcomes with their novel drug candidates.

Apogee Therapeutics (APGE) Earnings & Revenues

Historic Earnings Reports

APGE Stock 12 Month Forecast

Average Price Target

$93.57

▲(70.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","73":"$73","116":"$116","51.5":"$51.5","94.5":"$94.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$93.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$70.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,51.5,73,94.5,116],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.59,61.08307692307692,65.57615384615384,70.06923076923077,74.5623076923077,79.05538461538461,83.54846153846154,88.04153846153847,92.53461538461539,97.0276923076923,101.52076923076923,106.01384615384615,110.50692307692307,{"y":115,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.59,59.434615384615384,62.27923076923077,65.12384615384616,67.96846153846154,70.81307692307692,73.6576923076923,76.50230769230768,79.34692307692308,82.19153846153846,85.03615384615384,87.88076923076923,90.7253846153846,{"y":93.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,56.59,57.621538461538464,58.653076923076924,59.684615384615384,60.71615384615385,61.74769230769231,62.77923076923077,63.81076923076923,64.8423076923077,65.87384615384616,66.90538461538462,67.93692307692308,68.96846153846154,{"y":70,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":54.49,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.61,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.33,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.75,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >